Trial Profile
Effects of TNF-Alpha Antagonism (Etanercept) in Patients With the Metabolic Syndrome and Psoriasis
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Etanercept (Primary)
- Indications Psoriasis
- Focus Pharmacodynamics
- 03 Apr 2014 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.
- 25 Jun 2013 Planned end date changed from 1 Dec 2015 to 1 Dec 2014 as reported by ClinicalTrials.gov.
- 17 Dec 2012 Planned End Date changed from 1 Dec 2014 to 1 Dec 2015 as reported by ClinicalTrials.gov.